Several stakeholders in the field of biobank research are currently developing and evaluating innovative consent procedures, and in doing so refer to national and international guidelines that regulate biomedical research. The objectives of this study were to present (1) a synthesis of all consent issues mentioned or required in guidelines that are of potential relevance to biobank research and (2) a detailed overview of similarities and differences between these guidelines. This analysis considered a purposive sample of the nine most internationally recognised research guidelines plus a national checklist for developing consent forms. The synthesis of all included research guidelines found 41 issues of potential relevance to consent procedures in biobank research. The guidelines differ substantially with respect to (1) how comprehensively they address these consent issues, (2) their definition and explanation of the issues and (3) how directly or indirectly the issues are mentioned. The set of 41 consent issues presented in this paper should be further developed in a continuous process. Our findings on the differences among major research guidelines also raise the issue of a more systematic development and revision process for these guidelines. The presented set of content issues potentially relevant to consent in biobank research can inform the balanced development or evaluation of consent forms, as well as the development and revision of corresponding research guidelines.
INTRODUCTION
Informed, voluntary and valid consent is a requirement of almost all national and international guidelines and legislations that govern biomedical research. 1 This applies to diagnostic and therapeutic procedures in clinical and research settings as well as to the collection of samples and data in biobanks. 2 It aims to protect patients' and participants' rights and autonomy, and to maintain public trust in patient care and research.
Several stakeholders in the field of biobank research and whole genome sequencing are currently developing innovative consent documents and procedures. [3] [4] [5] [6] One of the major reasons why consent documents in biobank research differ from standard documents in the context of clinical research is the increasing number of research biobanks that presume long-term storage of biomaterials and data. Such materials and data can be used for future research projects which are today unspecified and to some extent unforeseen. Long-term storage and unforeseen research questions are characteristic of various types of biobank, such as population biobanks and disease-specific biobanks. In these cases, donors of biomaterials are asked to give a 'broad consent' to a framework for future research of certain types instead of the standard narrow consent to one specific research project. Consent documents, therefore, need to explain the breadth of consent and other elements of the framework for future research such as, for example, crossborder use of biomaterials and/or data, property rights, commercial use, and data protection. Although these innovative 'broad consent' forms from long-term biobanks may differ in content from standard consent documents in specific clinical or biobank research projects, many consent issues are relevant to both narrow and broad types of consent, such as the right to withdraw, information about the purpose of research, and the risks and benefits involved.
In deciding on the content of such consent forms and information brochures or procedures, decision makers often refer to national and international laws and widely recognised guidelines such as the Declaration of Helsinki that play a major role in regulating and/or governing biomedical research in general.
There is little existing research appraising biomedical research guidelines with respect to informed consent requirements; see, for example, the comparative analyses of guidelines for clinical research by Alex Capron that focuses on some purposively selected procedural aspects. 1 Regarding biobank-relevant research guidelines in general, there are a few comparative studies that discuss similarities as well as differences in wording and content and make recommendations on legal, ethical and social issues in biobank research. 4 7-11 Though none of these studies focused specifically on consent content, some indicate that international research guidance also differs in the requirements of consent for biobank research, for example, type of consent (narrow vs broad consent) and that there is a need for harmonisation, especially for international cooperation.
A more comprehensive, structured and comparative analysis of consent requirements in research guidelines should make two principal analyses missing from the existing body of research. First, a synthesis of all consent characteristics mentioned or required in widely recognised guidelines. The results of such a systematic and transparent synthesis of consent characteristics could be used inter alia to better inform the development and evaluation of consent procedures, and the development and revision of research guidelines themselves. Second, a detailed overview of similarities and differences between the considered guidelines regarding their specific requirements for consent characteristics and content. This overview would facilitate a critical analysis and discussion of variation among guidelines. The systematic synthesis of recognised research guidelines together with a critical analysis might improve the consistency and validity of future consent procedures. The consistency of consent procedures is of particular importance for biobank research that aims to use biomaterials from different national and international biobanks; see, for example, recent networked initiatives for building infrastructure in the field, such as the Biobanking and Biomolecular Resources Research Infrastructure (http:// www.bbmri.eu/) and the Public Population Projects in Genomics and Society, P3G (http://www.p3g.org). Furthermore, the constant improvement and adaptation of consent procedures are important to maintain public trust in biobank research.
This study presents results for the two analyses mentioned in the previous paragraph. The authors used the findings of the first analysis (the synthesis of guideline requirements) to evaluate existing consent documents of German biobanks, as reported elsewhere. 12 
METHODS

Selection of guidelines
For our analysis, we selected a purposive sample of nine internationally recognised legal and ethical guidelines that include requirements or recommendations for consent procedures in biomedical research (clinical research and/or biobank research). 2 13-19 For the national (German) context of the abovementioned analysis, 12 we referred to one further document, namely, a 'commented checklist' on informed consent for clinical studies with an annex on biobank research. 20 The nine selected guidelines were considered to be internationally recognised and of particular relevance to the development of consent forms for biobank research for the following reasons: (A) They represent legal regulations for biomedical research. For Europe, these were Directive 2001/20/EC and the 'Convention on Human Rights and Biomedicine' together with its 'Additional Protocol Concerning Biomedical Research' and the 'Recommendation Rec (2006)4 of the Committee of Ministers to member states on research on biological materials of human origin'. For the USA, these were the Codes of Federal Regulations for the Protection of Human Subjects (Title 45 Part 46 and Title 21 Food and Drugs,  Part 50 with a focus on subpart B 'Informed Consent of Human Subjects'); (B) They represent ethical guidance that informed the development of current legal regulations in Europe and/or the USA. These were the 'Declaration of Helsinki' from the World Medical Association, the 'Guideline for good clinical practice' from the International Conference on Harmonisation (ICH) and the 'International Ethical Guidelines for Biomedical Research Involving Human Subjects' from the Council for International Organizations of Medical Sciences (CIOMS); (C) They represent guidance on the governance of biobank research from an influential international body. This was the document 'Guidelines on Human Biobanks and Genetic Research Databases' from the Organisation for Economic Co-Operation and Development (OECD). Though some of these widely recognised guidelines primarily address clinical research, they were considered in our analysis because many consent requirements in biobank research are either similar to those in clinical research or relatively easy to translate into the context of biobank research.
We discussed the selection of research guidelines and its prima facie validity with another three external experts in ethics and law of biomedical research. Furthermore, most of the chosen guidelines are noted as important legal and ethical frameworks in key sources such as the Oxford Textbook of Clinical Research Ethics. 1 21 Data extraction and synthesis of findings One author (IH) screened the complete text of all 10 guidelines and extracted text passages that mentioned issues relevant to or at least applicable to the content of consent documents in biobank research. The two other authors (HK, DS) independently double-checked the identified text passages for relevance and applicability. Any initial ambiguity was discussed among all three authors and could be solved unanimously. Finally, a set of relevant text passages was agreed by all authors.
For the synthesis of consent requirements mentioned in the guidelines, one author (IH) analysed all relevant text passages to develop a framework of categories that differentiates all the consent requirements in a consistent and meaningful manner. An inductive, constant comparison approach was employed to develop the framework of categories. 22 23 Constant comparison means that mentions of issues of potential relevance to consent procedures in biobank research were identified in the text passages and similar mentions were grouped together in a constant process of comparisons between similar text passages from different guidelines. These grouped mentions form the basic data for the inductive development of categories for consent characteristics. Categories must be meaningful and consistent both in relation to the original text passages and in relation to the context, namely, the matrix of categories for all consent characteristics mentioned or required in guidelines. After a first set of categories was developed, the other authors (HK, DS) independently checked the validity of the categorisation. Open questions were resolved in meetings and discussions between all authors.
During this process of categorisation, we needed to slightly adapt the issues arising from the clinical study context to the biobank context. For instance, we revised the wording 'duration of participation in trial/study' to 'duration of participation or storage'. In some cases, we performed a synthesis of issues, for example, subsuming 'money or material goods', 14 'payment' and 'expenses', 19 'additional costs', 13 'incentives', 24 and 'allowance' 20 under 'Payment/allowance and additional costs'. We excluded generally important aspects of biomedical research that we did not consider relevant to the content of consent forms in biobank research, for example, 'trial treatment and random assignment' 19 and 'alternative procedures or courses of treatment'. 13 Furthermore, we excluded formal aspects such as 'title of the document' or 'date/signature'. 20 We also rated whether text passages directly or indirectly mentioned issues potentially relevant to consent documents in biobank research (see mention order in table 1). Direct text passages include for example mandatory or basic issues to be considered in consent procedures such as 'information on the human biological material and data to be collected, their intended uses, storage, transfer and their disposal technique'. 2 Indirect text passages were often found in guideline chapters focusing on topics other than informed consent. Other types of indirect mention of consent content include, for example, passages describing just one facet of a consent issue, and passages which needed to be further adapted to the biobank context as for the issue 'Biobank design and structure'. We made this distinction between direct and indirect mentions for two main reasons. First, this distinction emphasises and demonstrates that important guidance on adequate consent procedures is sometimes mentioned only indirectly. Second, this distinction allowed us to be as transparent as possible about how much interpretation on our side was included in the extraction and synthesis of Continued relevant consent issues. The identification and categorisation of indirect mentions of relevant information clearly involve more interpretation by the rater.
RESULTS
Synthesis of a set of issues potentially relevant to consent procedures in biobank research
The qualitative synthesis of 10 guidelines resulted in a framework of 41 issues potentially relevant to consent procedures in biobank research. These 41 issues were grouped into four main categories: (A) 'General information' covering inter alia the explanation of the type of research and its purpose, (B) 'Conditions of participation' including background on voluntary participation, consent conditions and scope, (C) 'Consequences of participation' comprising issues around risks and benefits and (D) 'Dealing with data and biomaterial' encompassing issues concerning data protection measures and cooperation with third parties (see table 1 ). Table 1 further lists the number and names of guidelines that mention each of the 41 issues directly or indirectly. Table 2 outlines consent issues for each main category by means of examples. The original guideline text passages for all 41 issues are available on request from the authors.
Similarities and differences among guideline documents and consent characteristics
The 10 research guidelines differ substantially with respect to (A) the comprehensiveness with which they deal with issues potentially relevant to biobank consent procedures, (B) the specification and explanation of the issues, (C) which guideline chapters describe the issues and (D) how directly or indirectly the issues are mentioned as relevant to the consent procedure. Table 3 demonstrates how comprehensively the 41 issues were treated in the 10 research guidelines. The three guidelines that either focused on biobank/genetic research or included comments on biobank-specific aspects were the most comprehensive. 2 14 20 There were differing definitions and explanations of particular issues. While all guidelines mention the issue 'Right to withdraw or alter consent/without disadvantage' they differ, for example, in how they specify the disadvantage, with some guidelines raising the rather abstract 'right' to medical care 16 17 and one explicitly highlighting the consequences with regard to the 'provision' of medical care 2 or the patient-physician relationship . Another example of variation in wording is given by the issue 'feedback on findings'. Some guidelines include very broad recommendation, such as that the consent procedure should consider 'any other' relevant aspects 24 or the 'implications' 2 of participation in biobank research (see full quotes R1-R3 in table 4).
Regarding the location of recommendations on consent issues, guidelines differ in their formulation of titles for consentspecific chapters (eg, 'Terms of participation' or 'Informed consent of trial subjects') and as to whether and where in the full guidelines they indirectly describe further relevant consent issues, and whether these are explicitly referred to in the consent-specific chapter. Some of these consent issues are located in chapters such as 'Custodianship, benefit sharing and intellectual property' or 'Access'
2 (see quotes R4 in table 4). Table 1 shows whether guidelines mention issues relevant to consent procedures directly or indirectly.
Indirect mentions of issues often also appear in text passages describing 'thick concepts' such as 'potential genetic discrimination or stigmatisation'
2 (see quote R5 in table 4). Though the OECD guideline does not mention the risk of genetic discrimination explicitly as an issue that should form part of the consent procedure, the reader might interpret it as a potential 'implication' of participation in biobank research. This is important because, as highlighted above, the same OECD guideline considers any such 'implications' as being part of the consent procedure. We considered this text passage an indirect mention of the issue 'Policy for genetic information/consent to genetic analyses' (issue D.5 in table 1). Other examples of such implications or 
DISCUSSION
This study presents a framework of 41 issues that are of potential relevance to consent procedures in biobank research. The framework is the result of a systematic comparison and synthesis of nine international guidelines on biomedical or biobank research and one national checklist for informed consent documents. The framework informs researchers, health professionals, policy makers and the interested public about differences among research guidelines regarding their comprehensiveness and their specification of potentially relevant consent issues.
In the following, we discuss (A) differences and similarities between the various guidelines and consent characteristics, (B) opportunities for a more systematic guideline development and revision process and (C) the need to further develop the set of issues potentially relevant to consent procedures. 
Differences and similarities between the various guidelines and consent characteristics
In general, differences between guidelines are justifiable and even desirable, for example, when they are written for different audiences, legislations and needs. For example, the guidelines selected for our analysis differ partly according to whether they address biomedical research in general or focus on biobank research in particular. However, it is less clear that guidelines which at least partly address the same topic should differ substantially in wording and emphasis or in the (strategic) placement of relevant content. The more substantial these variations are, the more they allow different (not always adequate) interpretations by the reader, and the more they force interested parties to search for implicit or hidden messages.
In our guideline comparison, we distinguished whether potentially relevant consent issues were mentioned directly or indirectly in the referred text passages (table 1). Our decisions on this distinction depended on our interpretation of each guideline text passage and discussion of ambiguity. How do other readers of research guidelines deal with this challenge? Apart from our methodological interest, it is worthwhile to consider the practical consequences. Further research might discover how the fact of explicit and implicit information in research guidelines is conceived of and dealt with by the reader. Does the possibility of multiple interpretations allow reasonable flexibility in designing consent procedures or reduce their quality, for example by omitting important content from consent forms?
Questions on systematic guideline development or revision
This raises the question of how a more evidence-based guideline development procedure for regulations in biomedical research could look. Evidence in a broader understanding is not restricted to clinical outcome data but refers to the best available body of information that supports sound and unbiased decision making. In this regard, a full set of issues potentially relevant to consent in clinical or biobank research, drawn from a synthesis of existing guidelines (as presented in this paper), would form an important source of information (evidence) for the development and revision of guidelines. Additionally, a systematic review of the literature and empirical studies would enable a search for further possibly relevant issues for inclusion in the guidelines (see next section).
A similar approach has been applied recently in the field of clinical guideline development in the case of dementia guidelines. First, it was demonstrated how to review and synthesise the literature on ethical issues in dementia care. 25 The main outcome of this synthesis was a set ('full spectrum') of 51 ethical issues with potential relevance to dementia care. In a condensed version, this full spectrum was employed as a framework to assess whether 12 national dementia guidelines addressed these ethical issues and, if so, how. 26 As for research guidelines, such a set of relevant ethical issues can form the basis for more systematically informed ('evidence-based') and transparent development and revision of guidelines.
The need to further develop the set of issues potentially relevant to consent procedures
The set of 41 issues presented in this paper could be further developed by distinguishing core criteria (eg, B.2, B.3 in table 1) and additional issues (eg, A.9, D.4, D.14 in table 1). Such a balanced set of consent issues could help, for example, to develop simplified consent documents which are adapted to their users' informational needs. 27 However, because such a distinction between 'core' and 'additional' consent issues can have a substantial impact on the practice of consent procedures, a legitimate body should develop such lists in a participatory process that reflects the increasing evidence from empirical consent research. 28 29 In another study published elsewhere, we used the set of consent issues presented in this paper to assess a sample of 30 German biobank consent documents. 12 For future empirical evaluation and improvement of biobank-specific consent documents, the set of 41 potentially relevant content issues could be expanded with assessment items for measuring the quality and readability of consent documents (eg, the IPDAS criteria 30 31 ). We emphasise that we do not suggest all the presented issues need to be addressed in every consent procedure. Sound evaluation studies would be helpful to demonstrate whether the inclusion of the suggested issues in consent procedures strengthens the validity of consent or, paradoxically, weakens it. 32 With this in mind, we now describe two further issues potentially relevant to biobank-specific consent documents that are not mentioned in at least two of the analysed guidelines: (A) Therapeutic/diagnostic misconception and (B) Information about the use of biospecimens and publication of research results. 26 (Italic emphasis by the authors) 'During the informed consent process, the HBGRD should provide potential participants with sufficient information on the nature, implications, foreseeable risks and benefits of their participation, so that they can realistically assess the implications of their participation and can make an informed decision on whether to participate' OECD 2009, 2 4.1 (Italic emphasis by the authors)
R4
→C.5 Benefit-sharing 'The operators of the HBGRD should provide participants with information about commercial products that may arise from research conducted using its resources, including human biological materials, data derived from the analysis of samples, data or other information provided by or about the participant. Information should also be provided on the benefits, if any, the participant may receive'
'The informed consent process should provide information to the potential participant in a simple and easily understandable manner and on a variety of subjects. Depending on the nature of the HBGRD, this may include: 'The HBGRD should develop a detailed policy of whether or not it intends to commercialise any resources, such as the human biological materials (e.g. specimens, samples), data, information, the database(s), etc. It is important that this information be communicated to the participant during the informed consent process. This policy should also explicitly set out whether participants will derive any benefits from the commercialisation' OECD 2009, 2 Annotations 2 9.79 R5 →D.5 Policy for genetic information/consent to genetic analyses 'Research pertaining to a large portion of a population, especially amongst those sharing common characteristics, may raise issues of potential discrimination and stigmatisation. For example, an association between a specific heritage and a particular disease may lead to discrimination from insurers or employers. The initiators and operators of the HBGRD should take into consideration potential consequences not only for participants but also individuals, families and groups who may not have participated in the HBGRD. In addition, the HBGRD should make information publicly available about the possibility that research results generated from population-based human genetic data may have repercussions for individuals, participants, their family, groups to which they belong and the community as a whole. 
[…] The protocol should include information regarding funding, sponsors, institutional affiliations, potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study' WMA 2013, 24 22 R8 →D.9 International cooperation/transborder use 'The HBGRD may also provide information about whether human biological materials and data will be made available for research pursuing commercial purposes or research carried out beyond national borders. The operators of the HBGRD need to ensure that data access requests and data distribution are consistent with the informed consent provided by the participant' 'HBGRDs can make an important contribution to the advancement of knowledge by participating in international endeavours and collaborations. One of the challenges facing international collaboration is establishing internationally accepted technological standards and norms. Some efforts are underway to develop international standards to facilitate the linkage of datasets and the interoperability of systems so as to foster research and the sharing of data and materials. However, in many areas there is no international Therapeutic/diagnostic misconception Therapeutic misconception means that study participants do not adequately understand that the main goal of participating in research is the gain of generalisable knowledge, sometimes without personal benefit for the individual participants. 33 34 For biobank or genetic research, one might argue that potential participants could have a diagnostic more than a therapeutic misconception. Though there is not much research on this phenomenon in the biobank field, a few empirical studies indicate that some research participants have misconceptions about participating in biobank research. These comprise, for example, the expectations or hope that potential health problems will be detected by free overall healthcare screening or monitoring and that individual-level research results will be given. 35 Therefore, consent procedures for biobank research might not be explicit enough about the fact that potential participants do not gain any personal or direct benefit from participation in a biobank, and could actively address undue expectations such as the diagnostic misconception. 35 Among the analysed guidelines, only CIOMS stated that a consent procedure should explain 'how the research differs from routine medical care' 14 (see quote D1 in table 4). But even in CIOMS, possible misconceptions were (if at all) addressed mostly 'between the lines'.
Information about the use of biospecimens and publication of research results
Though some guidelines mention this issue in their policies on publication or on public information or involvement procedures 2 16 24 (see quotes D2-D4 in table 4), it is not itself suggested as a consent issue. A recent review of ethical issues in biobank research explicitly addressed researchers' 'obligation to publish all relevant scientific information that could help the society as a whole'. 36 In the field of clinical research, Food and Drug Administration guidelines (21 CFR 50.25c) recently added the need to inform potential trial participants about trial registries and give them the possibility of learning about the trial's progress and its results 37 (see quote D5 in table 4). Our study has the following limitations. The identification and rating of the guideline text passages unavoidably involve interpretative judgements which could affect the validity and reliability of the results, namely, the 41 categories for consent issues that were initially developed by one author. We addressed this by having two other researchers who read all relevant text passages from the research guidelines and then discussed and further strengthened the validity of the categories. Furthermore, we restricted our analysis of guidelines to a purposive sample of guidelines that are either representing current law or are frequently referenced in clinical and biobank research. Many other national or context-specific guidelines exist that are less widely recognised, but could perhaps indicate further issues that are of potential relevance to consent procedures in biobank research. 38 Furthermore, our guideline comparison did not consider differences resulting from the legal status of the guidelines considered. However, even when these limitations are taken into account, we believe that our core findings, namely, the set of 'issues potentially relevant to consent procedures in biobank research' and the detected differences in guidelines remain valid and reliable.
In summary, we presented a systematically and transparently derived matrix of potentially relevant content issues for consent in biobank research. This matrix can inform the balanced development or evaluation of consent procedures and related consent documents, as well as the development and revision of corresponding research guidelines. 
